Comparative Pharmacology
Head-to-head clinical analysis: VICTOZA versus WEGOVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VICTOZA versus WEGOVY.
VICTOZA vs WEGOVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Semaglutide, a GLP-1 receptor agonist, increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and reduces appetite via central GLP-1 receptor activation.
Subcutaneous injection: 0.6 mg once daily for 1 week, then increase to 1.2 mg once daily. May further increase to 1.8 mg once daily if needed for glycemic control.
Subcutaneous injection 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly for 4 weeks, then 1 mg once weekly for 4 weeks, then 1.7 mg once weekly for 4 weeks, then maintenance 2.4 mg once weekly.
None Documented
None Documented
After subcutaneous administration, the terminal elimination half-life is approximately 13 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 1 week (6–8 days), supporting once-weekly subcutaneous dosing.
Liraglutide is eliminated via degradation by general proteolysis and not by specific enzymes; the intact drug is not excreted in urine or feces. Degraded metabolites are excreted via urine and feces.
Primarily renal; approximately 97% of the dose is excreted unchanged in urine, with less than 3% in feces via biliary excretion.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist